211 related articles for article (PubMed ID: 19394254)
21. Quinoxaline Moiety: A Potential Scaffold against
Montana M; Montero V; Khoumeri O; Vanelle P
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443334
[No Abstract] [Full Text] [Related]
22. Synthesis and in vitro evaluation of new ethyl and methyl quinoxaline-7-carboxylate 1,4-di-N-oxide against Entamoeba histolytica.
Duque-Montaño BE; Gómez-Caro LC; Sanchez-Sanchez M; Monge A; Hernández-Baltazar E; Rivera G; Torres-Angeles O
Bioorg Med Chem; 2013 Aug; 21(15):4550-8. PubMed ID: 23787289
[TBL] [Abstract][Full Text] [Related]
23. New agents active against Mycobacterium avium complex selected by molecular topology: a virtual screening method.
García-García A; Gálvez J; de Julián-Ortiz JV; García-Domenech R; Muñoz C; Guna R; Borrás R
J Antimicrob Chemother; 2004 Jan; 53(1):65-73. PubMed ID: 14645324
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and biological evaluation of new 2-arylcarbonyl-3-trifluoromethylquinoxaline 1,4-di-N-oxide derivatives and their reduced analogues.
Solano B; Junnotula V; Marín A; Villar R; Burguete A; Vicente E; Pérez-Silanes S; Aldana I; Monge A; Dutta S; Sarkar U; Gates KS
J Med Chem; 2007 Nov; 50(22):5485-92. PubMed ID: 17910426
[TBL] [Abstract][Full Text] [Related]
25. 2D QSAR Analysis of Substituted Quinoxalines for their Antitubercular and Antileptospiral Activities.
Natarajan R; Puratchikody A; Muralidharan V; Doble M; Subramani A
Curr Comput Aided Drug Des; 2019; 15(2):182-192. PubMed ID: 30317999
[TBL] [Abstract][Full Text] [Related]
26. QSAR modeling of the interaction of flavonoids with GABA(A) receptor.
Duchowicz PR; Vitale MG; Castro EA; Autino JC; Romanelli GP; Bennardi DO
Eur J Med Chem; 2008 Aug; 43(8):1593-602. PubMed ID: 18158201
[TBL] [Abstract][Full Text] [Related]
27. Structure-activity relationships in nitrothiophenes.
Morley JO; Matthews TP
Bioorg Med Chem; 2006 Dec; 14(23):8099-108. PubMed ID: 16887355
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and preliminary in vitro evaluation of antimycobacterial activity of new pyrrolo[1,2-a] quinoxaline-carboxylic acid hydrazide derivatives.
Guillon J; Reynolds RC; Leger JM; Guie MA; Massip S; Dallemagne P; Jarry C
J Enzyme Inhib Med Chem; 2004 Dec; 19(6):489-95. PubMed ID: 15662953
[TBL] [Abstract][Full Text] [Related]
29. Pyrimido[1,2-a]quinoxaline 6-oxide and phenazine 5,10-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi.
Lavaggi ML; Aguirre G; Boiani L; Orelli L; García B; Cerecetto H; González M
Eur J Med Chem; 2008 Aug; 43(8):1737-41. PubMed ID: 18068272
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis.
Vicente E; Villar R; Burguete A; Solano B; Pérez-Silanes S; Aldana I; Maddry JA; Lenaerts AJ; Franzblau SG; Cho SH; Monge A; Goldman RC
Antimicrob Agents Chemother; 2008 Sep; 52(9):3321-6. PubMed ID: 18625764
[TBL] [Abstract][Full Text] [Related]
31. Anti-tuberculosis activity of some N-pentopyranosylamines.
Moczulska A
Acta Pol Pharm; 2004; 61(4):259-62. PubMed ID: 15575591
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and evaluation of phenoxy acetic acid derivatives as [corrected] anti-mycobacterial agents.
Shaharyar M; Siddiqui AA; Ali MA
Bioorg Med Chem Lett; 2006 Sep; 16(17):4571-4. PubMed ID: 16784842
[TBL] [Abstract][Full Text] [Related]
33. Quinoxaline and quinoxaline-1,4-di-N-oxides: An emerging class of antimycobacterials.
Keri RS; Pandule SS; Budagumpi S; Nagaraja BM
Arch Pharm (Weinheim); 2018 May; 351(5):e1700325. PubMed ID: 29611626
[TBL] [Abstract][Full Text] [Related]
34. A QSAR study on 2-(4-methylpiperazin-1-yl)quinoxalines as human histamine H4 receptor ligands.
Sharma BK; Pilania P; Singh P; Prabhakar YS
J Enzyme Inhib Med Chem; 2011 Jun; 26(3):412-21. PubMed ID: 20939766
[TBL] [Abstract][Full Text] [Related]
35. Comparative QSAR- and fragments distribution analysis of drugs, druglikes, metabolic substances, and antimicrobial compounds.
Karakoc E; Sahinalp SC; Cherkasov A
J Chem Inf Model; 2006; 46(5):2167-82. PubMed ID: 16995747
[TBL] [Abstract][Full Text] [Related]
36. Quinoxaline 1,4-di-N-Oxide Derivatives: Are They Unselective or Selective Inhibitors?
Rivera G
Mini Rev Med Chem; 2022; 22(1):15-25. PubMed ID: 33573542
[TBL] [Abstract][Full Text] [Related]
37. Anti-
Palos I; Luna-Herrera J; Lara-Ramírez EE; Loera-Piedra A; Fernández-Ramírez E; Aguilera-Arreola MG; Paz-González AD; Monge A; Wan B; Franzblau S; Rivera G
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914062
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and antimicrobial evaluation of new 2-substituted 5,7-di-tert-butylbenzoxazoles.
Vinsova J; Cermakova K; Tomeckova A; Ceckova M; Jampilek J; Cermak P; Kunes J; Dolezal M; Staud F
Bioorg Med Chem; 2006 Sep; 14(17):5850-65. PubMed ID: 16784871
[TBL] [Abstract][Full Text] [Related]
39. Quantitative structure-activity relationships for small non-peptide antagonists of CXCR2: indirect 3D approach using the frontal polygon method.
Khlebnikov AI; Schepetkin IA; Quinn MT
Bioorg Med Chem; 2006 Jan; 14(2):352-65. PubMed ID: 16182534
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, characterization and in vitro antibacterial activity of new steroidal thiazolo quinoxalines.
Khan SA; Saleem K; Khan Z
Eur J Med Chem; 2007 Jan; 42(1):103-8. PubMed ID: 16997429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
